Biosciences

First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy

First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy Emalex Biosciences today announced that the first patient was dosed in its Expanded Access Program for ecopipam, an investigational first-in-class D1 receptor antagonist in development for…

Read MoreFirst Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy
Innovaccer

Innovaccer Launches Flow Capture to Bring Autonomous Coding to the Frontlines of U.S. Healthcare

Innovaccer Launches Flow Capture, Bringing Autonomous Coding to the Frontlines of American Healthcare Innovaccer, the leading healthcare AI company, launched Flow Capture, an autonomous medical coding solution designed to eliminate one of the most persistent bottlenecks in American healthcare: manual…

Read MoreInnovaccer Launches Flow Capture to Bring Autonomous Coding to the Frontlines of U.S. Healthcare
New Real-World

New Real-World Evidence Study Shows Leva® Pelvic Health System Significantly Improves Fecal Incontinence in Women

New Real-World Evidence Study Shows Leva® Pelvic Health System Significantly Improves Fecal Incontinence Symptoms in Women Axena Health, Inc., a women’s health company redefining the standard of care for pelvic health through clinically proven, non-invasive treatments, today announced the publication of a…

Read MoreNew Real-World Evidence Study Shows Leva® Pelvic Health System Significantly Improves Fecal Incontinence in Women
GoodRx

GoodRx Expands Employer-Sponsored Access to Zepbound KwikPen

GoodRx to Expand Employer-Sponsored Access to Zepbound® KwikPen® GoodRx  the leading platform for prescription savings in the U.S., today announced employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (for single-patient-use) through GoodRx Employer Direct. As one of Lilly’s Employer Connect independent program administrators, GoodRx…

Read MoreGoodRx Expands Employer-Sponsored Access to Zepbound KwikPen
MindWalk

MindWalk Introduces B Cell Llama™, Expanding Nanobody Discovery for Cell and Bispecific Therapies

MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era MindWalk Holdings Corp. a bio-native AI company, today announced B Cell Llama™, a platform for the discovery of VHH nanobodies: the single-domain antibody fragments…

Read MoreMindWalk Introduces B Cell Llama™, Expanding Nanobody Discovery for Cell and Bispecific Therapies
Savara

Savara Reports Regulatory Update for MOLBREEVI in Autoimmune PAP Treatment Development

Savara Provides Regulatory Update on MOLBREEVI Development Program for Autoimmune Pulmonary Alveolar Proteinosis Savara clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases, has announced a significant regulatory update regarding its investigational therapy MOLBREEVI, which is being developed…

Read MoreSavara Reports Regulatory Update for MOLBREEVI in Autoimmune PAP Treatment Development